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 A B S T R A C T 
Background: Liquid biopsy (LB) is a technique that utilizes circulating biomarkers from cancer patients to 
provide information regarding the genetic landscape of the cancer. LB is emerging as an alternative and 
complementary diagnostic and prognostic tool to surgical biopsy and is expected to provide the tool for the 
implementation of precision oncology in clinical settings. In fact, it may contribute to enhance 
understanding of tumor heterogeneity and permitting the dynamic monitoring of treatment responses and 
genomic variations. Thus, LB is a promising method for the management of cancer, including breast cancer 
(BC), whose incidence in Italy is progressively increasing. Previous studies focused mainly on patients with 
advanced-stage BC. In the present study we evaluated the number of circulating tumor cells (CTCs), the 
quantity of cell free tumor DNA (cftDNA) and the analysis of the mutational profile of DNA from CTCs 
(ctcDNA) and cftDNA in early stage BC patients. 
Methods: Matched pre- and post-surgery blood samples were collected from 47 early stage BC patients. 
CTCs enumeration was done using Isoflux system, molecular profile of ctcDNA and cftDNA was performed 
with the Spotlight 59 Panels kit on a MiSeq Illumina instrument. 
Results: Eighty percent of samples was CTCs-positive, while healthy controls were all CTCs-negative. 
Forty-four patients provided a pre-surgery and 21 post-surgery sample. By comparing the number of CTCs 
post-surgery with that of pre-surgery, we found that 66% of patients showed a decreased number of CTCs, 
14% of patients continued to have the same number of CTCs, while, interestingly, 19% of patients showed 
an increased number of CTCs. Next Generation Sequencing (NGS) of ctcDNA and cftDNA showed that 
52% of samples had mutations in 9 genes (TP53, CDKN2A, FBXW7, PTPN11, KRAS, NRAS, BRAF, 
IDH1, ALK) and in 5 genes (PIK3CA, APC ALK, KRAS, TSC1), respectively, with KRAS and ALK 
overlapping and TP53 being the most frequently mutated gene in ctcDNA analysis. 
Conclusions: LB could facilitate early detection of minimal residual disease, aiding in the initiation of 
adjuvant therapy to prevent recurrence and progression towards metastasis, enhance individualized 
treatment and longitudinal screening, thus improving the clinical management and outcome of patients with 
early BC. 
                                            © 2020 Antonio Rulli. Hosting by Science Repository. All rights reserved. 
 
Background 
Breast cancer (BC) is an invalidating disease with a serious physical and 
psychological impact. In Italy, increasing trends in BC incidence have 
been observed, so that today it represents the most common tumor 
(52,800 new cases in 2018), overcoming other major malignancies, such 
as colon and lung cancers (the so called “big killers”) [1]. Alarmingly, 
41% of the new diagnosed tumors applies to more and more young 
people (age < 50 years), a percentage out of the age expected for 
diagnostic mammographic screening (age > 50 years). The first cause of 
death in cancer patients is the metastatic spread of the tumor from the 
primary site. As known, this occurs through the release of tumor cells 
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into the blood circulation (circulating tumor cells, CTCs). There has been 
considerable interest in analyzing CTCs as a potential source of 
clinically actionable information relating to molecular profile of the 
patient’s disease. CTCs can be accessed repeatedly and noninvasively 
and, thus, provide a clinical feasible methodology for tracking 
longitudinal changes in disease profile that is not readily accomplished 
with conventional biopsy. In fact, this approach provides only a snapshot 
of the tumor restricted to the site and state of the cancer at the time of 
biopsy [2]. 
 
CTCs can enter and stay in the bloodstream long before tumor metastasis 
occurs and even at very early stage of cancer development [3, 4]. Hence, 
CTCs not only offer the potential to study the mechanism of cancer 
metastasis, but also allow ongoing monitoring of cancer progression and 
prediction of therapy response in a minimally-invasive way, which is 
referred to as liquid biopsy [5, 6]. To date, a number of studies have 
investigated the diagnostic and prognostic role of liquid biopsy, mainly 
through CTCs enumeration [5, 7]. In BC, CTCs represent a promising 
tool for identifying patients with high risk for tumor relapse in both 
metastatic and primary BC [8-12]. However, since the tumor is a 
“moving target”, with significant molecular alterations evolving during 
progression and in response to therapeutics, extending liquid biopsy to 
the genetic analysis of CTCs will further help to inform on these two 
relevant aspects of carcinogenesis and, consequently, to reduce 
mortality. In addition to CTCs, tumors can release DNA into the 
bloodstream, which is described as circulating tumor DNA (ctDNA) 
[13]. This cell-free DNA (cfDNA), although present also in healthy 
individuals, is significantly increased in cancer subjects [14]. Therefore, 
ctDNA is recognized as a novel biomarker in the diagnosis of several 
cancers, including gastric cancer, non-small lung cancer, and 
hepatocellular carcinoma [15-17]. In BC, the concentration of ctDNA 
has potential first diagnostic value for BC [13, 18]. Given that the 
combination of as many parameters as possible may lead to achieve the 
maximum level of diagnostic and/or prognostic accuracy, in the present 
study, we carried out liquid biopsy through CTCs enumeration, ctcDNA 
and cftDNA quantification and sequencing, in early BC patients before 
and after surgery (Figure 1), providing, for the first time to our 
knowledge, a complete picture, even though still limited to a small 
cohort of patients, of this potentially important diagnostic and prognostic 
strategy. 
 
Methods 
 
I Patients  
 
This is a prospective trial evaluating the liquid biopsy on women with 
operable BC admitted to the Breast Unit of the Santa Maria della 
Misericordia Hospital, Perugia, Italy. The study was reviewed and 
approved by the institution's Ethics Committee (Authorization CEAS 
Umbria #3068) and conducted in accordance with Good Clinical 
Practice Guidelines and the Declaration of Helsinki. Informed consent 
was obtained from all patients. Enrollment was strictly voluntary and 
patient results were blinded from investigators by use of a random 
number system as the unique patient identifier. Patients with metastatic 
disease and with other previous tumors or who underwent neo-adjuvant 
therapy were excluded from this study. Tumor stage was classified 
according to the American Joint Commission on Cancer (AJCC) tumor-
node-metastasis (TNM) classification and histopathological grading was 
assessed according to the modified Bloom–Richardson system [19]. 
Estrogen receptors (ERs) and progesterone receptors (PgRs) were 
assessed by immunohistochemistry (IHC) and were considered positive 
if at least 10% of the cells were stained. Tumors were considered HER2 
positive if they were scored 3+ by IHC or fluorescence in situ 
hybridization (FISH) amplified. 
 
II Blood Samples Collection 
 
Four whole peripheral blood (WPB) samples were collected from each 
patient before and after surgery. Two BD Vacutainer® K2 EDTA Tubes 
each of 7,5 ml of WPB were used for CTCs isolation and two PAXgene 
Blood DNA Tubes each of 10 ml WPB were used for cell-free tumor 
DNA (cftDNA) extraction (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Flow diagram of the study protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Flow diagram of the sampling and blood withdraw 
processing. 
 
III CTCs Isolation  
 
Two EDTA tubes were processed, within 30 min from the initial blood 
draw, for CTCs isolation. CTCs isolated from one blood tube underwent 
subsequent CTCs enumeration and those isolated from the second one 
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underwent subsequent lysis, whole genome amplification (WGA) and 
NGS analysis. CTCs isolation was performed by using the specific CTC 
Enrichment Kit (Fluxion Biosciences Inc, San Francisco, CA, USA), 
according to manufacturer’s instructions. Briefly, the peripheral blood 
mononuclear cell fraction was recovered by using LeucoSep tubes 
(Greiner Bio-One, Monroe, NC, USA) pre-treated with 15 ml of Ficoll-
Paque Plus (GE Healthcare, Pittsburgh, PA, USA) and resuspended in 1 
ml of binding buffer. Immunomagnetic beads pre-conjugated with anti-
EpCAM antibodies (CTC Enrichment Kit; Fluxion Biosciences Inc) 
were added directly to the sample and incubated for 2 hours at 4°C with 
passive mixing on a rotator. Following the magnetic bead coupling step, 
samples were loaded into the inlet well of the microfluidic cartridge in 
Isoflux system (Fluxion Biosciences Inc., San Francisco, CA, USA). 
Samples were flowed through the channel at a flow rate of 20 μl per 
minute by applying a head pressure of 2 psi to the inlet well in. Each 
sample passed through the channel in less than 45 minutes. After 
processing, the disk containing the cells in a hanging drop is inserted into 
a holder and the isolated target cells were recovered off the isolation zone 
disk through pipetting and dispensed into a microfuge tube for further 
processing [3]. 
 
IV CTCs Enumeration Analysis 
 
For enumeration, IsoFlux isolated target cells were recovered from the 
disk through pipetting and immunofluorescence staining was performed 
using anti-cytokeratin (CK), anti-CD45, and Hoechst 33342 (nucleus) 
by using IsoFlux CTC Enumeration Kit (Fluxion Biosciences Inc.) and 
following manufacturer’s instructions. Briefly, recovered CTCs were 
fixed with phosphate-buffered saline (PBS) buffer containing 1.8% 
formaldehyde, washed, and blocked with 1% donkey serum in PBS. 
Cells were stained with rabbit polyclonal anti-human CD45 antibody 
followed by goat anti-rabbit antibody conjugated with Cy3. After 
permeabilization with 0.1% Triton X-100, cells were stained with anti-
CK (fluorescein isothiocyanate). For CK staining, we used antibody 
clone CK3-6H5, a pancytokeratin-specific antibody likely to recognize 
all simple epithelium CKs. Stained CTCs were mounted in SlowFade 
Gold mounting media with Hoechst 33342 (Life Technologies Inc, 
Foster City, CA, USA) to Sensoplate Glass-Bottom Multiwell Plates 
(Greiner Bio-One) for imaging. Cells were scored as CTCs if they were 
CK+, CD45−, nucleated, and morphologically intact (Figure 3) [3]. 
Imaging and counting were performed using Cytation Imaging Reader 
(BioTek, Canada). 
 
V ctcDNA Extraction and Whole Genome Amplification (WGA) 
 
By using the IsoFlux NGS DNA Kit (Fluxion Biosciences Inc.), CTCs 
were lysed to obtain ctcDNA that was subsequently amplified by whole 
genome amplification (WGA) reaction, thus generating DNA samples 
amenable to NGS, according to manufacturer’s instructions [4]. 
Subsequently the  amplified ctcDNA was purified using QIAamp DNA 
Mini Kit (Qiagen S.p.A., Milan, Italy) and stored at -80°C until its use. 
 
VI cftDNA Extraction 
 
Two PAXgene Blood DNA Tubes, each of 10 ml of WPB, were 
collected from each patient and processed within 30 min from the initial 
blood draw for cftDNA extraction. Whole blood was first centrifuged at 
1900g for 15 min to separate the plasma from the peripheral blood cells. 
The supernatant was collected and transferred into a 2 mL Eppendorf 
tube (EP tube), followed by centrifugation at 1900 g for 10 min to pellet 
any remaining cells. Plasma (supernatant) was collected, transferred into 
a new 2 mL EP tube and stored at -80°C. The cftDNA was extracted 
from the plasma samples (at least 4 mL) using QIAamp MinElute 
ccfDNA Midi Kit using QIAcube instrument (Qiagen, S.p.A., Milan, 
Italy), according to the manufacturer’s instruction. The cftDNA was 
recovered in 55 μl of elution buffer and was stored at -20°C until its use. 
 
 
 
 
 
 
 
 
Figure 3: A circulating tumor cell (CTC). Cells are scored as CTCs if 
they are CK+ (green color), CD45- (pink color), nucleated (blue color), 
morphologically intact and vital. On the right side corner is evident a 
lymphocyte (CD45+) and nucleated (blue color). Magnification 40x. All 
around the CTC are shown capturing magnetic beads. 
 
 
 
 
 
 
 
 
 
 
 
      Contiguous, overlapping coverage is included for APC, ATM, 
EGFR, FBXW7, FGFR3, H3F3A, HNF1A, KIT, MSH6, PIK3CA, 
PTEN, SMAD4, and TP53. 
      Comprehensive coding exon coverage is included for TP53. 
Figure 4: Genes represented in the Spotlight 59 Oncology Panel and 
Number of Amplicons. 
 
VII ctcDNA and cftDNA by NGS  
 
For NGS analysis of both ctcDNA and cftDNA we used the Spotlight 59 
Panels (Fluxion Biosciences Inc, San Francisco, CA, USA), an oncology 
targeted amplification panel that includes 59 clinically-relevant 
oncology-related genes (Figure 4) [5]. For the preparation of high quality 
targeted NGS library, q-PCR on ABI 7300 Real-Time PCR System 
(Applied Biosystems) was performed using iTaq Universal SYBR Green 
Supermix and Alu115 and Alu247 primer pairs for an accurate 
quantification and quality evaluation of the starting DNA. Subsequent 
step is targeted amplification utilizing the Spotlight 59 kit, a single tube 
amplification reaction repeated over 2 technical replicates, each starting 
with a DNA input of 10 ng. The kit includes sample barcoding and 
provides the reagents required for full preparation of multiplex libraries. 
Accurate quantitation of libraries by Q-PCR was performed using 
NEBNext® Library Quant Kit (BioLabs Inc.) to maximize data output 
and quality from each sequencing run. Samples were then sequenced on 
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MiSeq Illumina instrument to a mean depth of 5,000x per replicate, 
10,000x per sample. Molecular profile analysis was determined using 
ERASE-Seq (Elimination of Recurring Artifacts and Stochastic Errors), 
a method for the accurate detection and sensitivity of low frequency 
DNA ranges. The Spotlight 59 panel and the ERASE-Seq workflow 
determine a sensitivity > 90% and < 0.1 false positives at 0.1% of the 
allele frequency [6]. 
VIII Statistical Analysis 
 
T-test, Cochran-Armitage test for trend or χ-square (without unknowns, 
if applicable), the statistical evaluation we employ, assesses the 
associations between the presence of CTC and the primary 
characteristics of the tumor. P values were two-tailed and considered 
significant if P < 0.05. 
 
Table 1: Presence of CTCs at baseline according to clinical-pathological variables. 
at-test 
bCochran-Armitage test for trend (without unknowns when appropriate) 
cχ2 test (without unknowns when appropriate) 
* Total CTCs n = 45 (for two patients no CTCs samples were available) **ki67 was considered high (> 20%) 
  All patients Patients without CTCs  Patients with CTCs P-value 
  (n = 47) (n = 9 )* (n = 36 )*  
  n  (%) n (%) n (%)  
Age (years)        
   Mean ± SD 54.4 ± 9.8 57 ± 8.2 53.8 ± 10.1 0.314a 
   Range 33-71 47-69 33-71  
Tumor stage       
   pT1 34 (72.3) 7 (77.8) 27 (75.0) 0.730b 
   pT2 7 (14.9) 1 (11.1) 5 (13.8)  
   pT3 2 (4.3) 0 2 (5.6)  
   pT4 1 (2.1)  - -  
   Unknown 3 (6.4) 1 (11.1) 2 (5.6)  
Nodal stage       
   pN0 30 (63.8) 4 (44.5) 25 (69.4) 0.163b 
   pN1 7 (14.9) 1 (11.1) 6 (16.7)  
   pN2 3 (6.4) 0 2 (5.6)  
   pN3 3 (6.4) 2 (22.2) 1 (2.7)  
   Unknown 4 (8.5) 2 (22.2) 2 (5.6)  
Histological grading     
   G1 13 (27.7) 3 (33.3) 10 (27.7) 0.738b 
   G2 25 (53.2) 5 (55.6) 18 (50)  
   G3 7 (14.9) 1 (11.1) 6 (16.7)  
   unknown 2 (4.2) 0 2 (5.6)  
Histological type       
   Ductal 39 (83) 5 (55.6) 32 (88.8) 0.562b 
   Lobular 5 (10.6) 3 (33.3) 2 (5.6)  
   In situ  3 (6.4) 1 (11.1) 2 (5.6)  
Hormone receptor status (ER, PgR)       
   Negative 5 (10.7) 0 5 (13.8) 0.299c 
   Positive 41 (87.2) 9 (100) 30 (83.5)  
   Unknown 1 (2.1) 0 1 (2.7)  
Ki67**       
   High 13 (27.7) 2 (22.2) 10 (27.8) 0.569c 
   Low 30 (63.8) 6 (66.7) 23 ( 63.9)  
   Unknown 4 (8.5) 1 (11.1) 3 (8.3)  
HER2 status       
   Negative 38 (80.9) 6 (66.7) 30 (83.4) 0.246c 
   Positive 5 (10.6) 2 (22.2) 3 (8.3)  
   Unknown 4 (8.5) 1 (11.1) 3 (8.3)  
Type of surgery        
   Breast conserving 34 (72.4) 7 (77.8) 26 (72.2) 0.550c 
   Mastectomy 13 (27.6) 2 (22.2) 10 (27.8)  
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Results 
 
I Patient Characteristics and Circulating Tumor Cell (CTCs) 
status 
 
In this explorative study we reported the preliminary results of 50 
patients enrolled at the Breast Unit of the Santa Maria della Misericordia 
Hospital in Perugia from April 2018 to February 2019. Of the 50 patients 
included in the study, 44 patients had infiltrative BC, 3 patients had in 
situ BC and 3 patients were healthy controls (Figure 1). Patient 
characteristics are described in (Table 1). The median diagnostic age of 
the 47 patients was 54 years (range 33-71 years) and all patients were 
female. The majority of patients (93.6%) had invasive carcinoma and the 
87.2% had ER/PR positive disease. There were no statistically 
significant associations between the number of CTCs and 
clinicopathological data (Table 1). In total, 45 patients with known CTCs 
status at baseline (for two pts CTCs status were not available) were 
included in the final analysis. One or more CTCs were detected in 80% 
(36 out of 45) of samples. All healthy controls were CTCs-negative.  
Among the three in situ BC patients two presented 1 and 3 CTCs, while 
1 had 0 CTCs. For only one patient, the number of CTC after surgery 
was available and showed the same number of CTCs before the 
treatment (n = 3). Among the infiltrative BC group, 44 patients provided 
a pre-surgery and 21 post-surgery sample. Hence, we enumerated CTCs 
in a total of 21 patients before and after surgical therapy. By comparing, 
in this group, the number of CTCs before and after surgery, we noticed 
that 66% of patients who presented CTCs before surgery showed a 
decreased number of CTCs after surgery (Table 2, Row A.). Conversely, 
14% of patients who were positive for CTCs before surgery, continued 
to have the same number of CTCs after surgery (Table 2, Row B.). 
Interestingly, 19% of patients who had a pre-surgery low number of 
CTCs showed an increased number of CTCs post-surgery (Table 2, Row 
C.). Total cftDNA was obtained for 22 samples. Levels of circulating 
tumor DNA varied; median concentration was 23 ng/µl (range 0.01-0.49 
ng/µl). The mean plasma mutant allele frequency (AF) ranged from 
0.22% to 2.01%. 
 
II Mutation profiling of ctcDNA and cftDNA by NGS 
 
We assessed by NGS the mutation profiling of ctcDNA and matching 
cftDNA in samples of patients taken prior surgery. Although we 
examined mutation hotspots in 59 genes by NGS, the preliminary results 
showed that 52% (11 out of 21) of ctcDNA samples analyzed had 
mutations in 9 genes (TP53, CDKN2A, FBXW7, PTPN11, KRAS, 
NRAS, BRAF, IDH1, ALK) and only one mutation in one gene was 
detected in the majority of samples. The patient 0022 had four mutations 
in four genes (ALK, KRAS, NRAS, CDKN2A). TP53 and ALK were 
the most frequently mutated genes. In the patient 0004, sequencing of 
ctcDNA revealed the presence of two mutations in TP53 gene 
(p.R282W, p.A161T) and 1 mutation in ALK gene (p.F1174C). Two 
patients who had 0 CTCs were sequenced as control and no mutations 
were found. The cftDNA was sequenced only for six patients and of 
them, three patients had mutations in 5 genes (PIK3CA, APC ALK, 
KRAS, TSC1) whereas in the remaining three patients no mutations 
were detected. In one patient (0015) who did not present mutations in 
the ctcDNA (CTC = 0) we determined 1 mutation in the APC gene 
(p.K1308*) from cftDNA plasma (Table 3).  
Table 2: Number of circulating tumor cells (CTCs) pre- and post-
surgery. 
A. Patients with CTCs number decreased after surgery 
 Number of CTCs/7.5 ml blood 
Patient ID Pre-surgery (A)* Post-surgery (B)** 
0008 28 0 
0013 10 1 
0014 7 0 
0044 6 0 
0005 6 1 
0037 4 0 
0006 7 4 
0029 7 3 
0026 3 2 
0036 5 3 
0004 2 0 
0020 1 0 
0042 3 1 
0049 7 2 
B. Patients with CTCs number persisted after surgery 
0003 1 1 
0017 3 3 
0018 3 3 
C. Patients with CTCs number increased after surgery 
0016 1 2 
0019 0 1 
0022 2 4 
0030 0 4 
*(A) sample collected pre-surgery; **(B) sample collected post-surgery 
 
Discussion 
 
Cancer therapy decisions are often made according to the 
histopathological-molecular profile of tumor tissue obtained from 
surgery or biopsy. It has been shown that tumor profiles change with 
time and treatment, and that tumor tissue is heterogeneous. Thus, other 
approaches that are easily accessible and less invasive than surgery or 
biopsy to monitor responses to treatment and predict relapses are 
urgently needed. In the last few years, the term "liquid biopsy" (LB) has 
been introduced to represent multifunctional circulating biomarkers in 
the peripheral blood and other physiological fluids of patients with 
cancer. LB is a noninvasive alternative to tissue biopsies, but it has not 
been implemented in routine clinical practice for BC. In addition, liquid 
biopsy seems to be a promising approach for personalized medicine, 
which enables the prediction, monitoring, and rational selection of 
appropriate therapy for individual patients. 
 
Although unequivocal evidence has shown the prognostic relevance of 
CTCs in the peripheral blood of patients with metastatic BC, less 
evidence is available for the prognostic relevance of CTCs at the time of 
primary diagnosis. In the present study, we conducted LB through CTCs 
enumeration, ctcDNA and cftDNA quantification and sequencing for 
mutational analysis in early BC patients before and after surgery (Figure 
1), providing, for the first time to our knowledge, the characterization, 
even though still limited to a small cohort of patients, of several 
prognostic tumor biomarkers, mirroring BC phenotype especially in its 
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evolution. Specifically, we found that surgery was able to decrease the 
number of CTCs in a significant percentage of patients (66%). On a 
biological point of view, this is consistent with the assumption that 
cancer feed the release of malignant cells into the bloodstream, hence the 
reduction or reset of CTCs mirrors the removal of the tumor source. 
Dissemination of tumor cells from the primary tumor into the 
bloodstream is a critical step in tumorigenesis and is considered a 
precursor of distant metastases [12]. CTCs have been defined “silent 
predictors of metastases”, this means that CTCs identifies “in progress” 
metastases onset, even before any other high-resolution imaging method 
is able to do [20]. 
 
 Hence, our results would suggest a potential resolution of the disease 
for those patients with no CTCs after surgery. Conversely, in 33% of 
patients the number of CTCs either remained unchanged or increased 
after surgical therapy. Hence, if the number of CTCs after surgery does 
not reset, the presence of distant micro-metastatic foci can be suspected 
that supply the circulatory torrent, with consequent persistence of the 
residual disease after surgery. In all cases, the enrolling of additional 
patients (which is ongoing in our laboratory) and the follow-up of those 
already collected are warranted, in order to prove our preliminary 
hypotheses from this explorative study. As above mentioned, isolation 
and characterization of the molecular profile of CTCs has the potential 
to provide a far easier liquid biopsy than tumor tissue biopsies to monitor 
malignant cell populations during disease progression and in response to 
therapies. Several CTCs capture and/or isolation technologies have been 
developed. The bead-based EpCAM antibody CTC capturing system is 
most widely used and one of them, Cell Search, the only Food and Drug 
Administration (FDA) approved device for CTCs analysis 
(enumeration), is considered the current “gold standard” [21].  
 
Table 3: ctcDNA and cftDNA mutations identified by NGS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, the performance and applicability of this system is receiving 
more and more challenge, especially regarding the capture rate (low cell 
recovery) and purity (low purity). Moreover, a key limitation of this 
technology is the ability to release and recover viable intact CTCs for 
downstream molecular analysis. Here, we successfully detected, counted 
and lysed CTCs (to get ctcDNA for subsequent NGS) from patients with 
early BC using the Isolation System Isoflux (Fluxion, San Francisco, 
CA). Although also Isoflux is an immunobead-based system, it has been 
projected to address Cell Search limitations, by providing high-
sensitivity rare cell isolation coupled with a novel cell retrieval 
microfluidic-based mechanism [2]. We, here, confirm that Isoflux 
provides a complete workflow to track oncogene mutational changes 
longitudinally with high success rates. Regarding the analysis of the 
mutation profiling of ctcDNA and matching cftDNA, our preliminary 
results refers to early-stage BC samples taken prior to surgery. This was 
a challenging issue of the study, since, as known, the fraction of ctcDNA 
and the total concentration of cftDNA are directly correlated with the 
stage of the disease and are significantly lower in earlier stages, which 
posed some technical issues in the extraction process and subsequent 
mutational analysis [22].  
 
Although we examined mutation hotspots in 59 genes by NGS, in the 
sequenced ctcDNA, the mutations were only detected in 9 genes (TP53, 
CDKN2A, FBXW7, PTPN11, KRAS, NRAS, BRAF, IDH1, ALK) and 
in the sequenced cftDNA, in 5 genes (PIK3CA, APC ALK, KRAS, 
TSC1). TP53 was the most frequently mutated gene (Figure 4). On a 
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biological point of view, this is consistent with the assumption that a 
non-functional TP53 has been shown to offer survival advantages to the 
cancer cells by eluding apoptosis, facilitating growth, conferring anoikis 
resistance, and the emergence of a potentially more aggressive 
malignancy [23]. TP53 mutations are exceptionally frequent in cancer 
and are among the key driving factors in triple-negative breast cancer 
(TNBC) [24]. Furthermore, TP53 mutations have been shown to predict 
a poor response to anthracycline-based neoadjuvant chemotherapy; 
others suggested that TP53 mutations confer sensitivity to taxane [25-
27]. A recent study suggested that patients with TP53 mutations are more 
likely to respond to anthracycline/cyclophosphamide-based neoadjuvant 
chemotherapy [28]. Another gene that is frequently mutated in BC 
patients is PIK3CA. Oshiro et al. reported that mutations in the PI3KCA 
gene could be targeted as a marker predictive of recurrence [29].  
 
In our study, at present, one patient (0022) had PIK3CA mutated (p. 
R93W) in the cftDNA. Although promising, this result is still far from 
being interpreted in the context of the literature due to the small number 
of patients (n = 6) characterized for their molecular profile by NGS. In 
addition, in this patient (0022) a different molecular profile of the 
ctcDNA compared to that of the cftDNA was found. It has been 
successfully demonstrated by single-cell sequencing that many breast 
cancers are composed of multiple distinct subclones [30]. Intra-patient 
cellular heterogeneity is widely reported in epithelial malignancies and 
it is expected that CTCs will also be heterogeneous [31]. Our results are 
consistent with previous findings which showed a heterogeneous pattern 
of genomic mutations on single ctcDNA or cftDNA obtained from 
several cancer patients, including BC ones.  
 
Conclusions 
 
This study showed that the enumeration of CTCs might be an important 
tool to monitor the progress of the disease and that the isolation of both 
ctcDNA and cftDNA from early BC patients can be used for genomic 
analysis, both to initially identify targetable mutations and to be used as 
a biomarker to reveal which cell populations are affected by the current 
or previous therapy. As required by our study protocol, collecting 
sequential blood samples for real-time monitoring of the efficacy of 
systemic therapies would offer new possibilities in evaluating targeted 
therapies based on genomic profiling of ctcDNA and cftDNA, so 
improving the clinical management of patients with early BC.  
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